ASMB - アセンブリ―・バイオサイエンシズ (Assembly Biosciences Inc.) アセンブリ―・バイオサイエンシズ

 ASMBのチャート


 ASMBの企業情報

symbol ASMB
会社名 Assembly Biosciences Inc (アセンブリ―・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アセンブリ・バイオサイエンス(Assembly Biosciences Inc.)はバイオテクノロジー会社である。同社はB型肝炎ウイルス(HBV)感染症の治療向け口腔治療薬及びジビオティックな微生物に健康を回復するように設計された経口合成生治療薬という2つのプラットフォーム・プログラムの開発に従事する。同社はHBVコア(HBc)タンパク質を直接的に標的とし、アロステリックに調節する低分子であるコアタンパク質アロステリックモジュレーター(CpAM)を発見した。マイクロビオムプログラムは、菌株の同定と選択プロセスを含む統合的プラットフォームと菌株の分離と増殖のための方法、下部胃腸(GI)管にライブ生物学的と従来の療法の標的経口送達を可能にする送達システムGEMICELを含む。このプラットフォームの主要製品候補であるAB-M101はクロストリジウム・ディフィシル感染症の治療薬として開発中である。   アセンブリ―・バイオサイエンシズは米国のバイオ医薬品会社。主にB型肝炎ウィルス(HBV)やクロストリジウム・ディフィシル(CDAD)などの感染症疾患の新治療薬の開発・商品化に焦点を当てる。研究開発施設をサンフランシスコ及びニューヨークに置く。本社はニューヨーク。   
本社所在地 11711 North Meridian Street Suite 310 Carmel IN 46032 USA
代表者氏名 Derek A. Small デレク・A・スモール
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 212-554-4388
設立年月日 38626
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 79人
url www.assemblybio.com
nasdaq_url https://www.nasdaq.com/symbol/asmb
adr_tso
EBITDA EBITDA(百万ドル) -68.11952
終値(lastsale) 26.02
時価総額(marketcap) 662117383.58
時価総額 時価総額(百万ドル) 643.79590
売上高 売上高(百万ドル) 12.75800
企業価値(EV) 企業価値(EV)(百万ドル) 551.12366
当期純利益 当期純利益(百万ドル) -66.93408
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Assembly Biosciences Inc revenues increased from $3M to $6.8M. Net loss increased 56% to $43.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase from $10.9M to $26.2M (expense) Stock-based Compensation in SGA increase from $1.1M to $9.5M (expense).

 ASMBのテクニカル分析


 ASMBのニュース

   A top biotech investor lays out why an entirely new approach to treating cancer and infections could finally pay off in 2021  2021/01/13 16:28:47 Business Insider
Summary List Placement 2021 could be the year of the microbiome. That's at least one top healthcare venture capitalist's prediction. Venrock partner Racquel Bracken anticipates more success will come for drugs tapping the mix of living microorganisms that live in and on our bodies. In December, Business Insider asked 29 VCs what they thought would happen in the healthcare industry in 2021 . Many turned their attention to the impacts of the pandemic on telemedicine, mental healthcare, or ongoing shifts toward consumer-driven and value-based care. Bracken, however, predicted microbiome drugs would make a comeback this year. The venture capitalist has put money behind that belief, investing in Federation Bio, a $50 million microbiome-based startup launched in late 2020. Business Insider identified four key microbiome players to watch that could make 2021 a com back year for the space. Companies are betting the bugs in our body can be used to treat diseases The microbiome, which refers to the community of bacteria living on and around the human body, drew a wave of investor and media interest in 2015, as more established biotech firms and newer startups touted new research showing the link between gut bacteria and a host of physical and mental health conditions, including irritable bowel syndrome, ulcerative colitis, autism, depression, and anxiety.
   Assembly Bio pivots away from microbiome program – Microbial Biotech News  2020/12/11 22:02:20 Microbial Biotech News
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced this week plans to pivot away from its microbiome program and allocate more resources towards advancing its hepatitis B virus (HBV) therapeutic pipeline.
   Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing  2020/11/17 13:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company…
   Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™ - Stocks News Feed  2020/11/13 13:00:00 Stocks News Feed
– Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic (pg) RNA as a key biomarker, as well as highlight Assembly Bio’s core inhibitor clinical pipeline – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting… Read More »Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
   Assembly Biosciences stock tanks 69% following Q3 earnings announcement – Microbial Biotech News  2020/11/08 16:23:19 Microbial Biotech News
Assembly Biosciences, Inc. (Nasdaq: ASMB) reported Q3 financial results on November 5, 2020 after market close for the period ended September 30, 2020
   A top biotech investor lays out why an entirely new approach to treating cancer and infections could finally pay off in 2021  2021/01/13 16:28:47 Business Insider
Summary List Placement 2021 could be the year of the microbiome. That's at least one top healthcare venture capitalist's prediction. Venrock partner Racquel Bracken anticipates more success will come for drugs tapping the mix of living microorganisms that live in and on our bodies. In December, Business Insider asked 29 VCs what they thought would happen in the healthcare industry in 2021 . Many turned their attention to the impacts of the pandemic on telemedicine, mental healthcare, or ongoing shifts toward consumer-driven and value-based care. Bracken, however, predicted microbiome drugs would make a comeback this year. The venture capitalist has put money behind that belief, investing in Federation Bio, a $50 million microbiome-based startup launched in late 2020. Business Insider identified four key microbiome players to watch that could make 2021 a com back year for the space. Companies are betting the bugs in our body can be used to treat diseases The microbiome, which refers to the community of bacteria living on and around the human body, drew a wave of investor and media interest in 2015, as more established biotech firms and newer startups touted new research showing the link between gut bacteria and a host of physical and mental health conditions, including irritable bowel syndrome, ulcerative colitis, autism, depression, and anxiety.
   Assembly Bio pivots away from microbiome program – Microbial Biotech News  2020/12/11 22:02:20 Microbial Biotech News
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced this week plans to pivot away from its microbiome program and allocate more resources towards advancing its hepatitis B virus (HBV) therapeutic pipeline.
   Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing  2020/11/17 13:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company…
   Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™ - Stocks News Feed  2020/11/13 13:00:00 Stocks News Feed
– Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic (pg) RNA as a key biomarker, as well as highlight Assembly Bio’s core inhibitor clinical pipeline – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting… Read More »Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
   Assembly Biosciences stock tanks 69% following Q3 earnings announcement – Microbial Biotech News  2020/11/08 16:23:19 Microbial Biotech News
Assembly Biosciences, Inc. (Nasdaq: ASMB) reported Q3 financial results on November 5, 2020 after market close for the period ended September 30, 2020
   A top biotech investor lays out why an entirely new approach to treating cancer and infections could finally pay off in 2021  2021/01/13 16:28:47 Business Insider
Summary List Placement 2021 could be the year of the microbiome. That's at least one top healthcare venture capitalist's prediction. Venrock partner Racquel Bracken anticipates more success will come for drugs tapping the mix of living microorganisms that live in and on our bodies. In December, Business Insider asked 29 VCs what they thought would happen in the healthcare industry in 2021 . Many turned their attention to the impacts of the pandemic on telemedicine, mental healthcare, or ongoing shifts toward consumer-driven and value-based care. Bracken, however, predicted microbiome drugs would make a comeback this year. The venture capitalist has put money behind that belief, investing in Federation Bio, a $50 million microbiome-based startup launched in late 2020. Business Insider identified four key microbiome players to watch that could make 2021 a com back year for the space. Companies are betting the bugs in our body can be used to treat diseases The microbiome, which refers to the community of bacteria living on and around the human body, drew a wave of investor and media interest in 2015, as more established biotech firms and newer startups touted new research showing the link between gut bacteria and a host of physical and mental health conditions, including irritable bowel syndrome, ulcerative colitis, autism, depression, and anxiety.
   Assembly Bio pivots away from microbiome program – Microbial Biotech News  2020/12/11 22:02:20 Microbial Biotech News
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced this week plans to pivot away from its microbiome program and allocate more resources towards advancing its hepatitis B virus (HBV) therapeutic pipeline.
   Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing  2020/11/17 13:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company…
   Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™ - Stocks News Feed  2020/11/13 13:00:00 Stocks News Feed
– Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic (pg) RNA as a key biomarker, as well as highlight Assembly Bio’s core inhibitor clinical pipeline – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting… Read More »Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
   Assembly Biosciences stock tanks 69% following Q3 earnings announcement – Microbial Biotech News  2020/11/08 16:23:19 Microbial Biotech News
Assembly Biosciences, Inc. (Nasdaq: ASMB) reported Q3 financial results on November 5, 2020 after market close for the period ended September 30, 2020

 関連キーワード  (医薬品 米国株 アセンブリ―・バイオサイエンシズ ASMB Assembly Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)